Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ficerafusp Alfa (BCA 101) in Combination With Nivolumab in Platinum Refractory Head and Neck Squamous Cell Carcinoma Patients Who Progressed Within 6 Months After Multimodal Treatment for Locally Advanced Disease ( BICARA)

NCT07529873 is registered in ClinicalTrials.gov with Groupe Oncologie Radiotherapie Tete et Cou as lead sponsor.

NCT NCT07529873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07529873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ficerafusp Alfa (BCA 101) in Combination With Nivolumab in Platinum Refractory Head and Neck Squamous Cell Carcinoma Patients Who Progressed Within 6 Months After Multimodal Treatment for Locally Advanced Disease ( BICARA)
Lead sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Phase
Phase 2
Overall status
Recruiting
Start date
March 3, 2026
Completion date
December 31, 2030
Enrollment
131 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of head and neck (scchn)